The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
Open accessAbstract
Significance: Chimeric antigen receptor T (CAR-T) cell therapy has produced promising results in clinical trials but has been challenged by the inability to control engineered cells once infused into the patient. Here we present a generalizable method of controlling CAR-T cells using peptide-engrafted antibody-based molecular switches that act as a bridge between the target cell and CAR-T cell. We show that switches specific for CD19 govern the activity, tissue-homing, cytokine release, and phenotype of switchable CAR-T cells in a dose-titratable manner using xenograft mouse models of B-cell leukemia. We expect that this method of tuning CAR-T cell responses will provide improved safety and versatility of CAR–T-cell therapy in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Fusion protein linkers: Property, design and functionality
Chen, X., Zaro, J. L., & Shen, W.-C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.039 · Cited by 2,056
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 2×
“Approaches to improving CAR–T-cell safety have included the use of kill switches that can eliminate CAR-T cells in the case of severe toxicity (13, 14).”
BackgroundMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 1×
“This design is identical to the second generation CAR used by June and coworkers in CART-19 (28).”
MethodMonoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Hudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M. C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 532
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Kalos, M., & June, C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.002 · Cited by 486
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 485
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Aalberse, R. C., & Schuurman, J. (2002) · Immunology · doi:10.1046/j.0019-2805.2001.01341.x · Cited by 449
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 377
Insights into the initiation of TCR signaling
Chakraborty, A. K., & Weiss, A. (2014) · Nature Immunology · doi:10.1038/ni.2940 · Cited by 353
Urbanska, K., Lanitis, E., Poussin, M., Lynn, R. C., Gavin, B. P., Kelderman, S., Yu, J., Scholler, N., & Powell, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3890 · Cited by 322
Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H. R., & Plückthun, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14130 · Cited by 290
Versatile strategy for controlling the specificity and activity of engineered T cells
Ma, J. S. Y., Kim, J. Y., Kazane, S. A., Choi, S.-H., Yun, H. Y., Kim, M. S., Rodgers, D. T., Pugh, H. M., Singer, O., Sun, S. B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524193113 · Cited by 273
Self-citationRedirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Tamada, K., Geng, D., Sakoda, Y., Bansal, N., Srivastava, R., Li, Z., & Davila, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1449 · Cited by 259
Designing chimeric antigen receptors to effectively and safely target tumors
Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 204
Zhang, H., Snyder, K. M., Suhoski, M. M., Maus, M. V., Kapoor, V., June, C. H., & Mackall, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4910 · Cited by 202
Terakura, S., Yamamoto, T. N., Gardner, R. A., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2012) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 191
Zahnd, C., Spinelli, S., Luginbühl, B., Amstutz, P., Cambillau, C., & Plückthun, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309169200 · Cited by 188
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Qin, H., Cho, M., Haso, W. M., Zhang, L., Tasian, S. K., Oo, H. Z., Negri, G. L., Lin, Y., Zou, J., Mallon, B. S., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612903 · Cited by 133
Engineered T cells for cancer therapy
June, C. H., Maus, M. V., Plesa, G., Johnson, L. A., Zhao, Y., Levine, B. L., Grupp, S. A., & Porter, D. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1568-1 · Cited by 126
Flanagan, R. J., & Jones, A. L. (2004) · Drug Safety · doi:10.2165/00002018-200427140-00004 · Cited by 124
Barrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 117
Adoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset Composition
Riddell, S. R., Sommermeyer, D., Berger, C., Liu, L., Balakrishnan, A., Salter, A. I., Hudecek, M., Maloney, D. G., & Turtle, C. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000036 · Cited by 114
Wang, R., Natarajan, K., & Margulies, D. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901276 · Cited by 114
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
Evans, A. G., Rothberg, P. G., Burack, R., Huntington, S. F., Porter, D. L., Friedberg, J. W., & Liesveld, J. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13562 · Cited by 106
Zhang, B. (2009) · mAbs · doi:10.4161/mabs.1.4.8895 · Cited by 79
Mössner, E., Koch, H., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4575 · Cited by 69
Classon, B. J., Brown, M. H., Garnett, D., Somoza, C., Barclay, A. N., Willis, A. C., & Williams, A. (1992) · International Immunology · doi:10.1093/intimm/4.2.215 · Cited by 61
Challenges in T cell receptor gene therapy
Uttenthal, B. J., Chua, I. C., Morris, E. C., & Stauss, H. J. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2637 · Cited by 51
Xu, X., Zhao, H., & Tang, Y. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.715350 · Cited by 46
Memory T cells in transplantation – progress and challenges
Li, X. C., Kloc, M., & Ghobrial, R. M. (2013) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283626130 · Cited by 36
Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties
Zhang, Y., Wang, D., de Lichtervelde, L., Sun, S., Smider, V. V., Schultz, P. G., & Wang, F. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303656 · Cited by 36
Self-citationFunctional human antibody CDR fusions as long-acting therapeutic endocrine agonists
Liu, T., Zhang, Y., Liu, Y., Wang, Y., Jia, H., Kang, M., Luo, X., Caballero, D., González, J., Sherwood, L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423668112 · Cited by 36
Self-citationYancopoulos, S., Yan, X., Agathangelidis, A., Li, W., Belessi, C., Ghia, P., Rosenquist, R., Davi, F., Oscier, D. G., Pospı́šilová, Š., et al. (2013) · Blood · doi:10.1182/blood.v122.21.4129.4129 · Cited by 35
Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond
Urbańska, K., & Powell, D. J. (2012) · OncoImmunology · doi:10.4161/onci.19730 · Cited by 17
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Metadata
- Authors
- Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y., Ramadoss, N. S., Hardy, I. R., Schulman, A., Du, J., Wang, F., Singer, O., Ma, J., Nunez, V., Shen, J., Woods, A. K., Wright, T. M., Schultz, P. G., Kim, C. H., & Young, T. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-01-12
- Volume
- 113
- Issue
- 4
- Pages
- E459-68
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2233225245
- Cited by
- 397
- References
- 51
- FWCI
- 22.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.